Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.

Tye, Sok Cin; de Vries, Sieta T; Wanner, Christoph; Denig, Petra; Heerspink, Hiddo J L

Tye, Sok Cin; de Vries, Sieta T; Wanner, Christoph; Denig, Petra; Heerspink, Hiddo J L.

Afiliação

Tye SC; Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, Netherlands.
de Vries ST; Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, Netherlands.
Wanner C; Division of Nephrology, Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
Denig P; Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, Netherlands.
Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, Netherlands.

Front Pharmacol ; 12: 786706, 2021.

Article em En | MEDLINE | ID: mdl-35145402

Palavras-chave

cardiovascular outcomes; diabetes; empagliflozin; kidney outcomes; risk markers

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google